Derivatives of substituted morpholines and uses thereof
A compound of Formula I includes a stereoisomer thereof and/or a salt thereof; wherein R 1 is a substituted alkane group, a heterocylic group, or a pyridine group; X is hydrogen, a halogen, an amino acid residue, a substituted amino acid residue, an alkyl group, or an ester. Such compounds may be used in pharmaceutical compositions and for the treatment of central nervous system (CNS) disorders:
1 . A method for treating a central nervous system disorder, the method comprising administering to a subject in need thereof a compound of Formula I, a stereoisomer thereof, or a salt thereof:
wherein:
R 1 is alkyl, heterocyclyl, or a pyridyl;
R 2 is alkyl, aryl, heteroaryl, or heterocyclyl;
R 3 -R 14 are each independently H, F, Cl, Br, I, CN, NO 2 , alkyl, aryl, heteroaryl, or heterocyclyl; and
X is halogen, an amino acid residue, a substituted amino acid residue, or ester, wherein X may also be H but only when R 1 is pyridyl.
2 . The method of claim 1 , wherein X is an amino acid residue.
3 . The method of claim 2 , wherein the amino acid residue is valine.
4 . The method of claim 3 , wherein R 1 is CH 2 , CH 3 CH, or (CH 3 ) 2 CHCH.
5 . The method of claim 1 , wherein the compound has the following structure:
6 . The method of claim 1 , comprising administering to the subject a salt of a compound having the following structure:
7 . The method of claim 1 , wherein the compound has the following structure:
8 . The method of claim 1 , wherein the compound has the following structure:
9 . The method of claim 1 , wherein the compound has the following structure:
10 . The method of claim 1 , wherein the compound has the following structure:
11 . The method of claim 1 , wherein the disorder is selected from the group consisting of depression, attention deficit hyperactivity disorder (ADHD), sleep disorders, apathy, cognition, anxiety, orthostatic hypotension, pain, and neurological disorders.
12 . The method of claim 1 , wherein the disorder is a sleep disorder.
13 . The method of claim 12 , wherein the administering is performed during an inactive or sleep phase.
14 . The method of claim 12 , wherein the sleep disorder is narcolepsy, cataplexy, or a REM sleep behavior disorder.
15 . The method of claim 1 , wherein the disorder is ADHD.
16 . The method of claim 1 , wherein the disorder is a neurological disorder selected from the group consisting of Parkinson's disease, Alzheimer's disease, Lewy body dementia, and multiple system atrophy.
17 . The method of claim 1 , wherein the disorder comprises pain.
18 . The method of claim 1 , wherein the disorder is a neuropsychiatric disorder.
19 . The method of claim 1 , wherein the disorder is anxiety or depression.